News
APA Welcomes National Focus on Mental Health, Urges Evidence-Based Approach and Continued Focus on Access to Care
6+ hour, 28+ min ago (202+ words) APA welcomes the attention placed squarely on the nation's mental health crisis and is committed to advancing solutions that improve access to high-quality evidence-based care. We are supportive of the Administration's plans for further investment in research and clinician training…...
"Network of Care" Launched by the Mississippi Department of Mental Health to Expand Access to Behavioral Health Services
1+ day, 9+ min ago (279+ words) JACKSON, Miss. , May 4, 2026 /PRNewswire/ -- The Network of Care for Behavioral Health program has been launched by the Mississippi Department of Mental Health (MDMH) to provide a statewide digital platform that improves access to behavorial health and community resources across all…...
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
19+ hour, 21+ min ago (343+ words) " Phase 2b Ongoing with topline data expected in 2 H 2027 " Presentation Highlights; Phase 2a Trial Design and Results Titration: Participants reached a mean pramipexole dose of 4. 1 mg within 8 days; 60% tolerated the maximum 5 mg dose by day 12. MADRS: ALTO-207 showed a statistically significant reduction…...
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
4+ day, 17+ hour ago (255+ words) SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- The latest Gene Sight" Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. ,(NASDAQ: MYGN), a leader inmolecular diagnostic testingand precision medicine, reveals that Americans feel mental health treatment isn't designed with them…...
ACTG Launches Landmark Study Evaluating Treatments for Depressive Disorders with or without Mild Neurocognitive Disorder among People Living with HIV
1+ week, 3+ day ago (851+ words) Yahoo Finance Oops, something went wrong U. S. markets close in 3h 17m ACTG Launches Landmark Study Evaluating Treatments for Depressive Disorders with or without Mild Neurocognitive Disorder among People Living with HIV CHAPEL HILL, N. C. , April 24, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network…...
Radial Expands to Seven Clinics with New Locations in Brooklyn and Spartanburg, SC
6+ day, 6+ hour ago (414+ words) NEW YORK, April 29, 2026 /PRNewswire/ --Radial today announced the opening of new clinics in Brooklyn's Williamsburg neighborhood and Spartanburg, SC " its 6th and 7th locations nationwide " bringing advanced, physician-led brain medicine to two new communities. A ribbon cutting will be held today in…...
Amae Health and Novant Health bring enhanced integrated care model for severe mental illness to Charlotte, North Carolina
1+ week, 5+ day ago (646+ words) The collaboration expands access to comprehensive outpatient behavioral health services for individuals with SMI in Mecklenburg County Amae Health | Novant Health Amae Health and Novant Health bring enhanced integrated care model for severe mental illness to Charlotte, North Carolina CHARLOTTE,…...
Comprehensive Healthcare Launches "Just In Time" Prescriber Scheduling to Improve Access to Behavioral Health Medication Services
3+ week, 2+ hour ago (261+ words) New model helps clients schedule prescriber appointments within days Under the Just In Time model, appointments are scheduled closer to the date of service rather than weeks in advance. Scheduling within a shorter timeframe gives providers greater flexibility to respond…...
Findings From Long-Term Analysis of the Effects of LYBALVI" (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
3+ week, 7+ hour ago (866+ words) " 56-Week Post Hoc Analysis Demonstrated Sustained Reduction in Hard-to-Treat Negative Symptoms " The analysis showed decreased negative symptoms over the first four weeks in a pooled analysis of treatment arms (LYBALVI, olanzapine and placebo) in ENLIGHTEN-1 with continued improvement over the…...
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
1+ mon, 1+ week ago (261+ words) Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry "Publication in JAMA Psychiatry provides independent peer-reviewed validation of our Phase 2b findings," said Dr. Velichka Valcheva, Chief Executive Officer. "This supports our ongoing efforts to advance GH001 into global…...